Cadrenal Therapeutics, Inc. entered into a separation agreement with Chief Medical Officer James J. Ferguson III, who will resign from his position effective July 31, 2026. The agreement includes salary payments through the separation date, COBRA premium coverage for up to six months, and reimbursement of approved business expenses. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with complex medical needs.
